Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 282 (Astegolimab) in Healthy Subjects and CRSwNP
NCT02170337Phase 1Completed
- Sponsor
- Amgen
- Start
- Jul 2014
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing AMG 282 with Placebo (2 arms). Primary endpoints: Safety and tolerability at 169 days and Immunogenicity at 169 days. Started Jul 2014; status: completed.
02
Drugs
astegolimab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT02170337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02170337.